SCHEMBL526315

SCHEMBL526315

Cc1ccc(S(=O)(=O)OS(=O)(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.50
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
CA12 O43570 1/20 0.46
CA3 P07451 1/20 0.46
CA6 P23280 1/20 0.46
CA5A P35218 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
DNMT1 P26358 1/20 0.45
CYP2D6 P10635 1/20 0.45
TLR9 Q9NR96 1/20 0.45
VDR P11473 1/20 0.44
MEN1 O00255 4/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL28278505 0.92 VDR (0.47) GAACA1CA2MMP1MMP2
SCHEMBL6490 0.86 GAA (0.59) GAACA1CA2MMP1MMP2
Water SCHEMBL3352692 0.84 GAA (0.56) GAACA1CA2MMP1MMP2
SCHEMBL30862469 0.84 GAA (0.56) GAACA1CA2MMP1MMP2
SCHEMBL528132 0.83 ALDH1A1 (0.50) GAACA1CA2MMP1MMP2
SCHEMBL527713 0.83 ALDH1A1 (0.50) GAACA1CA2MMP1MMP2
SCHEMBL21072819 0.81 ACHE (0.54) GAACA1CA2MMP1MMP2
SCHEMBL2966008 0.80 GAA (0.52) GAACA1CA2MMP1MMP2
SCHEMBL344977 0.80 GAA (0.52) GAACA1CA2MMP1MMP2
SCHEMBL66115 0.80 GAA (0.52) GAACA1CA2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3071191-B1 SLOW-RELEASE SOLID ORAL COMPOSITIONS GNOSIS SPA (IT) 2022-01-05 EP claimed
EP-3071191-A1 SLOW-RELEASE SOLID ORAL COMPOSITIONS Gnosis S.p.A. (IT) 2016-09-28 EP claimed
WO-2015071806-A1 SLOW-RELEASE SOLID ORAL COMPOSITIONS GNOSIS SPA (IT) 2015-05-21 WO claimed
EP-1754468-B1 Use of quaternary polysiloxanes in wash and personal care products CLARIANT PRODUKTE DEUTSCHLAND (DE) 2009-04-08 EP claimed
US-7511165-B2 Amino-functional silicone waxes CLARIANT FINANCE (BVI) LIMITED (VG) 2009-03-31 US claimed
US-20080242826-A1 Multiple Quartenary Polysiloxanes CLARIANT FINANCE (BVI) LIMITED (VG) 2008-10-02 US claimed
US-20070122372-A1 Amino-functional silicone waxes CLARIANT FINANCE (BVI) LIMITED (VG) 2007-05-31 US claimed
US-20070041930-A1 Use of quaternary polysiloxanes in cleaning and care compositions CLARIANT PRODUKTE (DEUTSCHLAND) GMBH) 2007-02-22 US claimed
EP-1678239-A1 AMINO-FUNCTIONAL SILICONE WAXES Clariant International Ltd. (CH) 2006-07-12 EP claimed
EP-1678238-A1 MULTIPLE QUATERNARY POLYSILOXANES Clariant International Ltd. (CH) 2006-07-12 EP claimed
WO-2005035631-A1 AMINO-FUNCTIONAL SILICONE WAXES CLARIANT INTERNATIONAL LTD (CH) 2005-04-21 WO claimed
WO-2005035628-A1 MULTIPLE QUATERNARY POLYSILOXANES CLARIANT INTERNATIONAL LTD (CH) 2005-04-21 WO claimed
US-20240145031-A1 Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators Precision Medicine Lab (NL) 2024-05-02 US disclosed
WO-2022268969-A1 ß-LACTAM ANTIBIOTIC WITH SIGNIFICANT ACTIVITY AGAINST CANCER E.G. COLON MALIGNANCIES UNIVERSITÄT REGENSBURG (DE) 2022-12-29 WO disclosed
EP-4108244-A1 SS-LACTAM ANTIBIOTIC WITH SIGNIFICANT ACTIVITY AGAINST CANCER E.G. COLON MALIGNANCIES Universität Regensburg (DE) 2022-12-28 EP disclosed
EP-3071191-B1 SLOW-RELEASE SOLID ORAL COMPOSITIONS GNOSIS SPA (IT) 2022-01-05 EP disclosed
US-4639468-A Derivatives of glycinamide, their preparation and their use CONTINENTAL PHARMA INC. (BE) 1987-01-27 US disclosed
EP-0000092-B1 METHOD OF PREPARING ASCORBIC ACID AND INTERMEDIATES SPECIALLY ADAPTED FOR USE THEREIN PFIZER INC. (US) 1981-04-29 EP disclosed
US-4115547-A ULTRAVIOLET LIGHT ABSORBERS WITH TWO OR MORE ESTER, THIOESTER AND/OR AMIDE GROUPS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1978-09-19 US disclosed
US-4002733-A WATER RESISTANCE MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1977-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070041930-A1 Use of quaternary polysiloxanes in cleaning and care compositions KRT18, POLR1C, CUTA GAA 3533/4885CA1 1720/4885CA2 2154/4885
US-20070122372-A1 Amino-functional silicone waxes PNISR, SRSF6, CUTA GAA 4453/4885CA1 4690/4885CA2 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.